NASDAQ:CGC

Canopy Growth Stock Competitors

$14.71
-0.12 (-0.81 %)
(As of 09/17/2021 04:00 PM ET)
Add
Compare
Today's Range
$14.55
$14.98
50-Day Range
$14.63
$22.23
52-Week Range
$13.83
$56.50
Volume2.60 million shs
Average Volume3.30 million shs
Market Capitalization$5.79 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.05

Canopy Growth (NASDAQ:CGC) Vs. TLRY, CRON, USNA, ACB, SNDL, and CDXC

Should you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include Tilray (TLRY), Cronos Group (CRON), USANA Health Sciences (USNA), Aurora Cannabis (ACB), Sundial Growers (SNDL), and ChromaDex (CDXC). These companies are all part of the "medicinals & botanicals" industry.

Canopy Growth (NASDAQ:CGC) and Tilray (NASDAQ:TLRY) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Volatility & Risk

Canopy Growth has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500. Comparatively, Tilray has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500.

Valuation and Earnings

This table compares Canopy Growth and Tilray's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$414.03 million13.97$-1,322,470,000.00($2.16)-6.81
Tilray$513.09 million10.61$-367,420,000.00($0.46)-26.46

Tilray has higher revenue and earnings than Canopy Growth. Tilray is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Canopy Growth and Tilray's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy Growth-200.71%-17.31%-10.94%
Tilray-104.82%-7.72%-4.57%

Institutional & Insider Ownership

14.2% of Canopy Growth shares are held by institutional investors. Comparatively, 11.3% of Tilray shares are held by institutional investors. 0.1% of Canopy Growth shares are held by insiders. Comparatively, 3.2% of Tilray shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Canopy Growth and Tilray, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth110302.14
Tilray08502.38

Canopy Growth currently has a consensus price target of $31.3444, indicating a potential upside of 113.08%. Tilray has a consensus price target of $16.6750, indicating a potential upside of 37.02%. Given Canopy Growth's higher probable upside, research analysts clearly believe Canopy Growth is more favorable than Tilray.

Summary

Tilray beats Canopy Growth on 10 of the 14 factors compared between the two stocks.

Canopy Growth (NASDAQ:CGC) and Cronos Group (NASDAQ:CRON) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Risk & Volatility

Canopy Growth has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500.

Earnings and Valuation

This table compares Canopy Growth and Cronos Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$414.03 million13.97$-1,322,470,000.00($2.16)-6.81
Cronos Group$46.72 million47.74$-73,140,000.00($0.38)-15.72

Cronos Group has lower revenue, but higher earnings than Canopy Growth. Cronos Group is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Canopy Growth and Cronos Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy Growth-200.71%-17.31%-10.94%
Cronos Group-258.59%-9.48%-8.36%

Institutional & Insider Ownership

14.2% of Canopy Growth shares are held by institutional investors. Comparatively, 13.9% of Cronos Group shares are held by institutional investors. 0.1% of Canopy Growth shares are held by company insiders. Comparatively, 5.5% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Canopy Growth and Cronos Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth110302.14
Cronos Group32101.67

Canopy Growth presently has a consensus target price of $31.3444, indicating a potential upside of 113.08%. Cronos Group has a consensus target price of $8.70, indicating a potential upside of 45.61%. Given Canopy Growth's stronger consensus rating and higher possible upside, equities analysts clearly believe Canopy Growth is more favorable than Cronos Group.

Summary

Canopy Growth beats Cronos Group on 8 of the 14 factors compared between the two stocks.

Canopy Growth (NASDAQ:CGC) and USANA Health Sciences (NYSE:USNA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Risk & Volatility

Canopy Growth has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500.

Earnings and Valuation

This table compares Canopy Growth and USANA Health Sciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$414.03 million13.97$-1,322,470,000.00($2.16)-6.81
USANA Health Sciences$1.13 billion1.57$124.66 million$5.8615.17

USANA Health Sciences has higher revenue and earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Canopy Growth and USANA Health Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy Growth-200.71%-17.31%-10.94%
USANA Health Sciences11.09%33.65%23.22%

Institutional & Insider Ownership

14.2% of Canopy Growth shares are held by institutional investors. Comparatively, 54.8% of USANA Health Sciences shares are held by institutional investors. 0.1% of Canopy Growth shares are held by company insiders. Comparatively, 0.2% of USANA Health Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Canopy Growth and USANA Health Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth110302.14
USANA Health Sciences00103.00

Canopy Growth presently has a consensus target price of $31.3444, indicating a potential upside of 113.08%. USANA Health Sciences has a consensus target price of $126.00, indicating a potential upside of 41.70%. Given Canopy Growth's higher possible upside, equities analysts clearly believe Canopy Growth is more favorable than USANA Health Sciences.

Summary

USANA Health Sciences beats Canopy Growth on 10 of the 14 factors compared between the two stocks.

Canopy Growth (NASDAQ:CGC) and Aurora Cannabis (NYSE:ACB) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Risk & Volatility

Canopy Growth has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 3.17, meaning that its stock price is 217% more volatile than the S&P 500.

Earnings and Valuation

This table compares Canopy Growth and Aurora Cannabis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$414.03 million13.97$-1,322,470,000.00($2.16)-6.81
Aurora Cannabis$207.89 million6.32$-2,468,190,000.00($2.86)-2.32

Canopy Growth has higher revenue and earnings than Aurora Cannabis. Canopy Growth is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Canopy Growth and Aurora Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy Growth-200.71%-17.31%-10.94%
Aurora Cannabis-895.36%-11.19%-8.64%

Institutional & Insider Ownership

14.2% of Canopy Growth shares are held by institutional investors. Comparatively, 17.2% of Aurora Cannabis shares are held by institutional investors. 0.1% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Canopy Growth and Aurora Cannabis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth110302.14
Aurora Cannabis66001.50

Canopy Growth presently has a consensus target price of $31.3444, indicating a potential upside of 113.08%. Aurora Cannabis has a consensus target price of $7.5850, indicating a potential upside of 14.40%. Given Canopy Growth's stronger consensus rating and higher possible upside, equities analysts clearly believe Canopy Growth is more favorable than Aurora Cannabis.

Summary

Canopy Growth beats Aurora Cannabis on 9 of the 14 factors compared between the two stocks.

Canopy Growth (NASDAQ:CGC) and Sundial Growers (NASDAQ:SNDL) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Risk & Volatility

Canopy Growth has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500. Comparatively, Sundial Growers has a beta of 6.18, meaning that its stock price is 518% more volatile than the S&P 500.

Earnings and Valuation

This table compares Canopy Growth and Sundial Growers' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$414.03 million13.97$-1,322,470,000.00($2.16)-6.81
Sundial Growers$45.48 million26.47$-178,920,000.00($0.26)-2.79

Sundial Growers has lower revenue, but higher earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Sundial Growers, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Canopy Growth and Sundial Growers' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy Growth-200.71%-17.31%-10.94%
Sundial Growers-707.37%-23.14%-20.54%

Institutional & Insider Ownership

14.2% of Canopy Growth shares are held by institutional investors. Comparatively, 9.2% of Sundial Growers shares are held by institutional investors. 0.1% of Canopy Growth shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Canopy Growth and Sundial Growers, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth110302.14
Sundial Growers14001.80

Canopy Growth presently has a consensus target price of $31.3444, indicating a potential upside of 113.08%. Sundial Growers has a consensus target price of $0.7333, indicating a potential upside of 1.15%. Given Canopy Growth's stronger consensus rating and higher possible upside, equities analysts clearly believe Canopy Growth is more favorable than Sundial Growers.

Summary

Canopy Growth beats Sundial Growers on 9 of the 14 factors compared between the two stocks.

Canopy Growth (NASDAQ:CGC) and ChromaDex (NASDAQ:CDXC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Risk & Volatility

Canopy Growth has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500. Comparatively, ChromaDex has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Canopy Growth and ChromaDex, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth110302.14
ChromaDex00303.00

Canopy Growth presently has a consensus target price of $31.3444, indicating a potential upside of 113.08%. ChromaDex has a consensus target price of $13.00, indicating a potential upside of 92.02%. Given Canopy Growth's higher possible upside, equities analysts clearly believe Canopy Growth is more favorable than ChromaDex.

Earnings and Valuation

This table compares Canopy Growth and ChromaDex's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$414.03 million13.97$-1,322,470,000.00($2.16)-6.81
ChromaDex$59.26 million7.79$-19,920,000.00($0.33)-20.52

ChromaDex has lower revenue, but higher earnings than Canopy Growth. ChromaDex is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Canopy Growth and ChromaDex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy Growth-200.71%-17.31%-10.94%
ChromaDex-37.51%-76.33%-44.17%

Institutional & Insider Ownership

14.2% of Canopy Growth shares are held by institutional investors. Comparatively, 29.8% of ChromaDex shares are held by institutional investors. 0.1% of Canopy Growth shares are held by company insiders. Comparatively, 11.8% of ChromaDex shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Canopy Growth beats ChromaDex on 7 of the 13 factors compared between the two stocks.


Canopy Growth Competitors List

Competitor NameBTM RankShare PriceAnalysts' Price TargetMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Tilray logo
TLRY
Tilray
2.0$12.17
-1.3%
$16.68
-37.0%
$5.44 billion$513.09 million-6.512,100Analyst Report
News Coverage
Cronos Group logo
CRON
Cronos Group
1.5$5.98
-0.7%
$8.70
-45.6%
$2.23 billion$46.72 million-14.57665
USANA Health Sciences logo
USNA
USANA Health Sciences
2.2$88.92
-1.6%
$126.00
-41.7%
$1.78 billion$1.13 billion13.411,943Analyst Upgrade
Analyst Revision
News Coverage
High Trading Volume
Aurora Cannabis logo
ACB
Aurora Cannabis
1.4$6.63
-0.2%
$7.67
-15.7%
$1.31 billion$207.89 million-0.452,731Upcoming Earnings
Analyst Report
News Coverage
Sundial Growers logo
SNDL
Sundial Growers
1.3$0.73
-1.4%
$0.73
-1.1%
$1.20 billion$45.48 million-1.25394News Coverage
ChromaDex logo
CDXC
ChromaDex
1.8$6.77
-6.6%
$13.00
-92.0%
$461.69 million$59.26 million-18.30110Analyst Report
News Coverage
HEXO logo
HEXO
HEXO
1.6$2.04
-0.0%
$6.86
-236.2%
$311.57 million$60.46 million-1.35N/A
MediWound logo
MDWD
MediWound
1.8$3.56
-1.7%
$7.13
-100.1%
$96.96 million$21.76 million-10.1775
Natural Alternatives International logo
NAII
Natural Alternatives International
1.5$14.91
-5.8%
N/A$95.71 million$118.88 million10.01175Upcoming Earnings
BON
Bon Natural Life
0.0$9.91
-7.0%
N/A$84.80 million$18.22 million0.008,787
GRVI
Grove
0.0$5.29
-0.8%
N/A$75.73 millionN/A0.0090Short Interest ↓
News Coverage
Gap Down
Mannatech logo
MTEX
Mannatech
1.8$32.92
-6.1%
N/A$62.32 million$151.41 million10.52226Ex-Dividend
High Trading Volume
HAPP
Happiness Biotech Group
1.4$1.08
-1.9%
N/A$34.51 million$71.49 million36.00151
This page was last updated on 9/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.